Insulin-like growth factor binding proteins (IGFBPs) in breast cancer

Journal of Mammary Gland Biology and Neoplasia

Volumn 5, Issue 1, 2000, Pages 75-84

  Perks, Claire M ^a   Holly, Jeff M P ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Breast cancer; Expression; IGFBPs; Modulation; Prognostic indicators

Indexed keywords

20 EPI 22 ETHOXY 24A,26A,27A TRIHOMO 9,10 SECOCHOLESTA 5,7,10(19) TRIEN 23 YNE 1ALPHA,3BETA,25 TRIOL; ANTIESTROGEN; AROMATASE INHIBITOR; CATHEPSIN D; ESTROGEN; FULVESTRANT; GESTAGEN; GONADORELIN AGONIST; HORMONE RECEPTOR AFFECTING AGENT; ICI 82780; LETROZOLE; MEGESTROL ACETATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE; PROMEGESTONE; PROSTATE SPECIFIC ANTIGEN; RETINOIC ACID; RETINOID X RECEPTOR; SEOCALCITOL; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D DERIVATIVE;

APOPTOSIS; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER RISK; CANCER STAGING; CELL PROLIFERATION; DRUG INHIBITION; DRUG MECHANISM; GROWTH INHIBITION; HOMEOSTASIS; HORMONAL REGULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN SYNTHESIS REGULATION; REVIEW;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II;

EID: 0033843445     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009519400591     Document Type: Review

References (92)

1. Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product
2. Insulin-like growth factors and their binding proteins: Biological actions
3. Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells
4. Expression of IGF-I and IGF-II mRNA in breast tissue
5. Molecular and cellular aspects of the insulin-like growth factor 1 receptor
6. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer
7. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
8. Crosstalk between the insulin-like growth factors and estrogens in breast cancer
9. Insulin-like growth factor-binding proteins: A proposed superfamily
10. IGF binding protein-3 and the acid-labile subunit: Formation of the ternary complex in vitro and in vivo
11. Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit
12. Recombinant insulin-like growth factor-binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells
13. Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line
14. Estrogen and antiestrogen modulation of MCF-7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media
15. Insulin-like growth factor-binding protein 3 (IGF-BP-3) inhibits estrogen-stimulated breast cancer cell proliferation
16. Plasminogen binds the heparin-binding domain of insulin-like growth factor binding protein-3
17. Plasmin degradation of insulin-like growth factor-binding protein-5 (IGFBP-5): Regulation by IGFBP-5-(201-218)
18. Insulin-like growth factor-binding protein-5 binds to plasminogen activator inhibitor-I
19. IGF binding proteins: Regulation of cellular actions
20. 1 integrin by means of its Arg-Gly-Asp sequence
21. Insulin-like growth factor-binding protein (IGFBP-3) and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells
22. Glycosaminoglycan binding characteristics of the insulin-like growth factor-binding proteins
23. Insulin-like growth factor binding proteins
24. Binding of mutants of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6
25. Identification of insulin-like growth factor binding proteins in breast cancer cells
26. Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: Correlation with estrogen receptor status
27. Identification of the insulin-like growth factor-binding proteins 5 and 6 (IGFBP-5 and 6) in human breast cancer cells
28. Insulin-like growth factor-binding proteins in human breast cancer tissue
29. IGFBP-3 gene expression and estrogen receptor status in human breast carcinoma
30. Detection of insulin-like growth factor-binding proteins (IGFBPs) by ligand blotting in breast cancer tissues
31. Insulin-like growth factor-binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease-free survival
32. Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells
33. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: Detection of higher levels in tumors with poor prognostic features
34. Prognostic value of prostate specific antigen for women with breast cancer - A large U.S. cohort study
35. Insulin-like growth factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer
36. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast
37. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
38. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen stimulated proliferation of human breast cancer cells
39. Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells
40. Estrogen and progesterone regulate secretion of insulin-like growth factor-binding proteins by human breast cancer cells
41. Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture
42. Alterations in plasma IGF-I caused by hormone manipulation of relevance to the mechanism of action and acquired resistance to endocrine treatment in breast cancer?
43. Influence of tamoxifen on the plasma levels of insulin-like growth factor-binding protein I in breast cancer patients
44. Tamoxifen reduces serum insulin-like growth factor I (IGF-I)
45. Influence of treatment with Tamoxifen and change in tumor burden on the IGF-system in breast cancer patients
46. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients
47. The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels
48. The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer
49. Influence of treatment with onapristone on the IGF-system in breast cancer patients
50. Effects of treatment with megesterol acetate, aminoglutethimide or formestane on insulin-like growth factor-I and -II, IGF-binding proteins and insulin-like growth factor-binding protein-3 protease status in patients with advanced breast cancer
51. Prostate-specific antigen (PSA) is an insulin-like growth factor-binding protein-3 protease found in seminal plasma
52. Prostate specific antigen - New applications in breast and other cancers
53. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue
54. Prostate-specific antigen (PSA) in women
55. Prostate specific antigen levels in nipple aspirate fluid correlate with breast cancer risk
56. Clinical relevance of the urokinase plasminogen activator system in breast cancer
57. Tissue extraction procedures for investigation of urokinase plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in human breast carcinomas
58. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind the IGFs inhibits the mitogenic effects of IGF-I and insulin
59. Cathepsin D: A protease involved in breast cancer metastasis
60. Reversal of cathepsin D routing modulation in MCF-7 breast cancer cells expressing antisense insulin-like growth factor II (IGF-II)
61. Interactions of cathepsin-D and insulin-like growth factor-II (IGF-II) on the IGF-II/mannose-6-phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-H
62. Modulation of cathepsin-D and pS2 protein levels in human breast cancer cell lines
63. Acid-activated insulin-like growth factor-binding protein-3 proteolysis in normal and transformed cells. Role of cathepsin D
64. Insulin-like growth factor-binding protein 3 mediates retinoic acid- and transforming growth factor-beta 2-induced growth inhibition in human breast cancer cells
65. Insulin-like growth factor-binding protein 3 mediates retinoic acid- and transforming growth factor-beta 2-induced growth inhibition in human breast cancer cells
66. Insulin-like growth factor-binding protein-3 in breast cyst fluid: Relationships with insulin-like growth factors I and II and transforming growth factor-beta 1 and 2
67. IGF-independent regulation of breast cancer growth by IGF binding proteins
68. Identification of glycosylated 38-kDa connective tissue growth factor (IGFBP-related protein 2) and proteolytic fragments in human biological fluids, and upregulation of IGFBP-rP2 expression by TGF-beta in Hs578T human breast cancer cells
69. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor
70. Tumor necrosis factor alpha enhances secretion of transforming growth factor-beta 2 in MCF-7 breast cancer cells
71. 1,25 dihydroxyvitamin D3 enhances the expression of transforming growth factor-beta 1 and its latent form binding protein in cultured breast carcinoma cells
72. Anti-estrogen induced synthesis of transforming growth factor-beta in breast cancer patients
73. Regulation of insulin-like growth factor (IGF) binding protein-5 in the T47D human breast carcinoma cell line by IGF-I and retinoic acid
74. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells
75. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor-binding protein-3
76. Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation
77. A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780
78. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor-binding protein 3 autocrine loop in human breast cancer cells
79. Insulin-like growth factor I (IGF-I)-binding protein complex is a better mitogen than free IGF-I
80. Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-I in cultured choriocarcinoma cells
81. Insulin-like growth factor-binding protein-3 induces apoptosis in MCF-7 breast cancer cells
82. Development of resistance to insulin-like growth factor-binding protein-3 in transfected T47D breast cancer cells
83. Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: Use of IGFBP-1 as an inhibitor of insulin-like growth factor action
84. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition
85. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF dependent manner
86. Oncogenic ras causes resistance to the growth inhibitor insulin-like growth factor binding protein-3 (IGFBP-3) in breast cancer cells
87. Differential IGF-independent effects of insulin-like growth factor-binding proteins (1-6) on apoptosis of breast epithelial cells
88. Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: Kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule
89. Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates phosphorylation of the IGFBP-5 receptor
90. Nuclear localization of insulin-like growth factor-binding protein 3 in a lung cancer cell line
91. Direct functional interactions between IGFBP-3 and RXR regulate gene expression and cellular apoptosis
92. Induction of the growth inhibitor IGF-binding protein 3 by p53